Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for OBX-115 (Engineered TIL Therapy) in Advanced Melanoma. The expected timing is based on the latest available company guidance and may change.
04/14/26:- Registration-enabling topline data expected by Year-End 2027.
Verification
Confirm timing and program details against the company announcement or filing.